What's new?

Added 6 hours ago Drug news

FDA accepts NDA for Libervant Buccal Film for the treatment of seizure clusters. -Aquestive Therapeutics.

Aquestive Therapeutics, Inc. announced that, as anticipated, the FDA accepted the Company’s New Drug Application (NDA) for Libervant (diazepam) Buccal...

Added 1 day ago Drug news

FDA approves Vyepti for migraine prevention.- Lundbeck

Lundbeck has announced that Vyepti (eptinezumab-jjmr) has been approved by the FDA for the preventive treatment of migraine in adults...

Added 1 day ago Drug news

FDA approves Anjeso to treat moderate to severe pain.- Baudax Bio

Baudax Bio, Inc. announced that the FDA has approved the New Drug Application (NDA) for Anjeso (meloxicam injection), which is...

Added 1 day ago Drug news

FDA approves Nexletol to treat heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease - Esperion.

Esperion has announced that the FDA approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. Nexletol...

Added 1 day ago Drug news

Interim data from the SIERRA trial of Iomab-B shows side effect differences in Acute Myeloid Leukemia patients.- Actinium Pharma

Actinium Pharmaceuticals announced findings from the SIERRA trial of Iomab-B (monoclonal antibody BC8 / I-131) in Elderly Relapse/Refractory Acute Myeloid...

Added 1 day ago Drug news

FDA approves Trulicity to reduce major adverse cardiovascular events in type 2 diabetes patients Eli Lilly

The FDA has approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2...

Added 2 days ago Drug news

Intra-Cellular Therapies, Inc. announced the publication in JAMA Psychiatry of Caplyta trial (ITI-007-301) in adult patients with schizophrenia.

Intra-Cellular Therapies, Inc. announced the publication of results from its Caplyta (lumateperone) clinical trial (ITI-007-301) in adult patients with schizophrenia....